AG
BMRN icon

Aperio Group’s BioMarin Pharmaceuticals BMRN Stock Holding History

Aperio Group’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		$3.52M Sell
40,132
-5,398
-12% -$428K 0.01% 989
2020
Q3 		$3.46M Sell
45,530
-2,707
-6% -$274K 0.01% 879
2020
Q2 		$5.95M Buy
48,237
+2,188
+5% +$217K 0.02% 665
2020
Q1 		$3.89M Buy
46,049
+11,980
+35% +$1.03M 0.02% 758
2019
Q4 		$2.88M Sell
34,069
-1,499
-4% -$113K 0.01% 932
2019
Q3 		$2.4M Sell
35,568
-27,601
-44% -$2.13M 0.01% 975
2019
Q2 		$5.41M Buy
63,169
+7,370
+13% +$630K 0.02% 686
2019
Q1 		$4.96M Sell
55,799
-2,378
-4% -$220K 0.02% 705
2018
Q4 		$4.95M Sell
58,177
-2,001
-3% -$190K 0.03% 647
2018
Q3 		$5.84M Sell
60,178
-801
-1% -$80K 0.03% 625
2018
Q2 		$5.74M Buy
60,979
+7,756
+15% +$679K 0.03% 612
2018
Q1 		$4.32M Sell
53,223
-347
-0.6% -$29.8K 0.02% 705
2017
Q4 		$4.78M Buy
53,570
+147
+0.3% +$12.8K 0.02% 655
2017
Q3 		$4.97M Sell
53,423
-3,068
-5% -$271K 0.03% 612
2017
Q2 		$5.13M Buy
56,491
+5,006
+10% +$455K 0.03% 567
2017
Q1 		$4.52M Buy
51,485
+2,492
+5% +$222K 0.03% 588
2016
Q4 		$4.06M Sell
48,993
-1,294
-3% -$111K 0.03% 581
2016
Q3 		$4.65M Buy
50,287
+5,488
+12% +$517K 0.03% 561
2016
Q2 		$3.48M Buy
44,799
+142
+0.3% +$12.1K 0.03% 629
2016
Q1 		$3.68M Buy
44,657
+12,688
+40% +$1.03M 0.03% 586
2015
Q4 		$3.35M Buy
31,969
+5,364
+20% +$560K 0.03% 580
2015
Q3 		$2.8M Buy
26,605
+5,148
+24% +$688K 0.03% 616
2015
Q2 		$2.94M Buy
21,457
+3,335
+18% +$413K 0.03% 588
2015
Q1 		$2.26M Buy
18,122
+3,298
+22% +$349K 0.03% 640
2014
Q4 		$1.34M Buy
14,824
+2,742
+23% +$228K 0.02% 782
2014
Q3 		$872K Buy
12,082
+975
+9% +$64.1K 0.01% 911
2014
Q2 		$691K Buy
11,107
+609
+6% +$36.8K 0.01% 991
2014
Q1 		$716K Buy
+10,498
New +$774K 0.01% 1163
2013
Q4 		– Sell
-7,181
Closed -$488K – 1091
2013
Q3 		$518K Buy
7,181
+2,772
+63% +$184K 0.01% 1129
2013
Q2 		$246K Buy
+4,409
New +$275K 0.01% 1389

Other funds holding BMRN

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Aperio Group's BMRN Position: Q4 2020 in Review

Aperio Group reduced its BioMarin Pharmaceuticals (BMRN) stake by 12% in Q4 2020, selling an estimated $428K and leaving 40,132 shares worth $3.52M. The position accounts for 0.01% of the portfolio, ranked #989.

Aperio Group first reported a position in BMRN in Q2 2013 and has held it in 30 quarters since. The position peaked at $5.95M in Q2 2020. 538 funds tracked by Wall St. Rank hold BMRN as of Q4 2020.

  • Aperio Group held 40,132 shares of BioMarin Pharmaceuticals worth $3.52M as of Q4 2020.
  • Aperio Group sold 5,398 BioMarin Pharmaceuticals shares in Q4 2020, an estimated $428K.
  • BioMarin Pharmaceuticals made up 0.01% of Aperio Group's portfolio in Q4 2020, its #989 holding.
  • Aperio Group first reported a position in BioMarin Pharmaceuticals in Q2 2013 and has held it in 30 quarters since.
  • Aperio Group's BioMarin Pharmaceuticals position peaked at $5.95M in Q2 2020.
  • 538 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q4 2020.

Based on Aperio Group's 13F filing for Q4 2020, filed 5 Feb 2021.